SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) announced today its flagship live-cell encapsulation technology can be successfully used to produce therapeutic antibodies. In completed animal studies, encapsulated cells were shown to produce antibodies that exited the capsules providing therapeutic effect and more importantly were capable of neutralizing viral infections.
